Advertisement

Ovarian Cancer

Identification three LncRNA prognostic signature of ovarian cancer based on genome-wide copy number variation.

Jan 31, 2020

Ovarian cancer is one of the most common malignant tumors of the female reproductive system, which seriously threatens the health of patients. It is of great significance to identify biomarkers to imp...

Overcoming Resistance to Platinum-Based Drugs in Ovarian Cancer by Salinomycin and Its Derivatives-An In Vitro Study.

Jan 30, 2020

Polyether ionophore salinomycin (SAL) and its semi-synthetic derivatives are recognized as very promising anticancer drug candidates due to their activity against various types of cancer cells, includ...

Strong Evidences of the Ovarian Carcinoma Risk in Women after IVF Treatment

Jan 30, 2020

In-vitro fertilization (IVF) has been very popular since the birth of the first "test-tube" baby. This method is the last hope and the most serious solution for couples with infertility problems. Alth...

Should MMMT still be treated with adjuvant taxane-based combination chemotherapy?

Jan 30, 2020

Malignant mixed Mullerian tumors of endometrial (MMMT-E) and ovarian (MMMT-O) origin are associated with poor prognosis. Suggestively epithelial-driven tumors, their treatment has shifted from anthrac...

Trabectedin (Yondelis®) as a Therapeutic Option in Gynecological Cancers: A Focus on its Mechanisms of Action, Clinical Activity, and Genomic Predictors of Drug Response.

Jan 30, 2020

The use of predictive biomarkers provides potential individualized cancer therapeutic options to prevent therapy failure as well as serious toxicities. Several recent studies showed that predictive an...

PRMT1 Is Recruited via DNA-PK to Chromatin Where It Sustains the Senescence-Associated Secretory Phenotype in Response to Cisplatin.

Jan 30, 2020

Protein arginine methyltransferase 1 (PRMT1) is overexpressed in various human cancers and linked to poor response to chemotherapy. Various PRMT1 inhibitors are currently under development; yet, we do...

Hyperthermic intraperitoneal chemotherapy for ovarian cancer: The heat is on.

Jan 23, 2020

Patients with advanced epithelial ovarian cancer have a high incidence of peritoneal disease recurrence despite maximal efforts to surgically remove all visible tumor plus intravenous chemotherapy. Th...

Treatment of recurrent epithelial ovarian cancer.

Jan 23, 2020

The majority of patients with advanced ovarian cancer progress after first-line therapy and require further treatment. Tumor biology, prior chemotherapy, responses to previous therapy, performance sta...

Surgery in recurrent ovarian cancer.

Jan 23, 2020

Ovarian cancer is one of the most challenging diseases in gynecologic oncology. The presentation of frequent recurrences requires the establishment and further development of therapy standards for thi...

New strategies in ovarian cancer treatment.

Jan 23, 2020

Insights from basic science dissecting carcinogenesis in the fallopian tube and ovary have led to a deeper understanding of the origin, molecular characteristics, and types of ovarian cancers. This lo...

Hyperthermic intraperitoneal chemotherapy does not improve survival in advanced ovarian cancer.

Jan 23, 2020

Despite its widespread use, until recently, there was no randomized evidence for hyperthermic intraperitoneal chemotherapy (HIPEC) versus surgery without HIPEC for ovarian cancer. Recently, a Dutch st...

SUBSPECIALTIES

Advertisement